- This event has passed.
Towards Accelerating Strategies for Hepatitis B Elimination: Increasing Vaccination Among Adults in High-Impact Settings
November 1, 5:00 am – 3:00 pm PDT
The Forum for Collaborative Research is pleased to invite students and faculty to our adult hepatitis B vaccination event: Towards Accelerating Strategies for Hepatitis B Elimination: Increasing Vaccination Among Adults in High-Impact Settings. This symposium, a collaborative project with UC Berkeley School of Public Health, is a one-day event in Atlanta, Georgia and online to produce recommendations for implementation of the universal adult hepatitis B vaccination for US adults aged 19–59, following guidance from the Advisory Committee on Immunization Practices. This symposium will strengthen the national strategy for adult hepatitis B prevention through high-level discussions among our major partnering organizations, including the Hepatitis B Foundation, Coalition for Global Hepatitis Elimination, Immunize.org, National Viral Hepatitis Roundtable, CDC Division of Viral Hepatitis, among others.
The symposium will feature 1) presentations from national viral hepatitis policy organizations, 2) panel discussion on major implementation gaps featuring health departments, corrections researchers, and community-based organizations, and 3) focused breakout group discussions for meeting attendees to strategize on implementation recommendations, with particular attention to high-impact communities such as incarcerated populations, Asian and African immigrant communities, and injection drug users.
Berkeley Public Health students and faculty are welcome to register for virtual attendance.
About the Forum for Collaborative Research
Founded in 1997, The Forum for Collaborative Research at the UC Berkeley School of Public Health is a public/private partnership with a mission to catalyze clinical development and improve global health by facilitating research, informing policy, and advancing regulatory science. The Forum’s three-pronged approach (practice, research, education) accelerates safe drug development by increasing clarity, cooperation and innovation, while maintaining standards of evidence. Forum members work in clinical practice, research, academia, industry, regulatory authorities, and patient advocacy. Using proven models for stakeholder engagement they enhance clinical trial efficiency, support fair participation, and expand access programs. Current projects focus on transplantation associated virus infections (TAVI), viral hepatitis B (HBV), human immunodeficiency virus (HIV), nonalcoholic fatty liver disease (NAFLD)/ nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), ocular diseases, and rare diseases.
Thank you to current and former Division of Infectious Diseases and Vaccinology students for organizing this event: Mitchell Leus, MPH ’22; Mayland Treat, MPH ’23; Aliya Mahmoud, MPH ’23.
If you require an accommodation for effective communication (ASL interpreting/CART captioning, alternative media formats, etc.) or information about campus mobility access features in order to fully participate in this event, please contact Mayland Treat at email@example.com with as much advance notice as possible and at least 7-10 days in advance of the event.